A recent decision by the Fifth Circuit Court of Appeals has restricted access to the abortion pill mifepristone, requiring it to be obtained in person rather than through mail or telemedicine. This ruling temporarily reverses a 2023 FDA regulation that allowed the pill to be sent by mail, impacting states where abortion is banned. The decision stems from a lawsuit by Louisiana, which argues that the FDA’s rule undermines its abortion ban. Mifepristone, part of a two-pill regimen to end pregnancies, was previously made more accessible during the COVID-19 pandemic. The appellate court’s order overrides a lower court’s pause on the case, with Louisiana’s Attorney General supporting the decision, while the ACLU and New York’s Attorney General criticize it for limiting abortion access. The ruling reflects ongoing legal battles over abortion rights in the U.S., following the Supreme Court’s 2024 decision to reject restrictions on mifepristone but leaving room for further challenges.
QUESTION: How might the restriction of mail-order access to mifepristone impact individuals in states with strict abortion laws?
US Supreme Court asked to restore abortion pill access
